

ASX Release

Anatara 4C and Updated Cash Balance

Key points:

- End of March 4C lodged
- Updated cash balance of \$14.35 million
- Revenues from lead product Detach™
-

BRISBANE, 14th April 2016: Anatara Lifesciences (ASX:ANR) is pleased to advise an updated cash balance of \$14.35 million, up \$2.184 million on the cash reported in the end of March 4C. Revenues generated from the commercialisation of Anatara's lead product Detach™ has resulted in a jump in the company's cash reserves.

Chairman, Dr Mel Bridges said, "We are delighted to be generating revenue at this early stage from our lead product. Anatara maintains a very strong cash position and is ideally placed to execute on its accelerated growth plans," he added.

For more information please contact:

<p>General inquiries Mel Bridges Chairman, Anatara Lifesciences +61 (0) 413 051 600 melbridges@parmacorp.com</p> <p>Paul Schober CEO, Anatara Lifesciences +61 (0) 412 026 657 pschober@anataralifesciences.com</p>	<p>Media inquiries Gavin Lower Buchan Consulting +61 (0) 3 8866 1215 glower@buchanwe.com.au</p>
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------

About Anatara Lifesciences

Anatara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.

Appendix 4C – 3rd Quarter

Quarterly Report for Entities Admitted on the Basis of Commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of Entity:

Anatara Lifesciences Ltd (ASX: ANR)

ABN:

41 145 239 872

Quarter Ended ('Current Quarter')

31st March 2016

Consolidated Statement of Cash Flows

<u>Cash Flows Related to Operating Activities</u>		Current Quarter SA'000	Year-to-Date (9 months) SA'000
1.1	Receipts from customers	-	-
1.2	Payments for:		
	(a) staff costs (including R&D staffing costs)	(247)	(748)
	(b) advertising/marketing/investor relations	-	-
	(c) research and development (excluding R&D staffing costs)	(248)	(591)
	(d) leased assets	-	-
	(e) other working capital	(239)	(819)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	81	202
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes refund	-	-
1.7	R&D Tax Concession refund	-	165
Net Operating Cash Flows		(653)	(1,791)

+ See chapter 19 for defined terms.

For personal use only

Appendix 4C
Quarterly Report for Entities
Admitted on the Basis of Commitments

		Current Quarter \$A'000	Year-to-Date (9 months) \$A'000
1.8	Net Operating Cash Flows (carried forward)	(653)	(1,791)
<u>Cash Flows Related to Investing Activities</u>			
1.9	Payment for acquisition of:		
	(a) businesses (item)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (provide details if material)	-	-
Net Investing Cash Flows		-	-
1.14	Total Operating and Investing Cash Flows	(653)	(1,791)
<u>Cash Flows Related to Financing Activities</u>			
1.15	Proceeds from issues of shares, options, etc.	38	8,616
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings	-	-
1.19	Dividends paid	-	-
1.20	Other (Capital Raising Costs)	-	(156)
Net Financing Cash Flows		38	8,460
Net Increase / (Decrease) in Cash Held		(615)	6,669
1.21	Cash at beginning of quarter/year to date	12,781	5,497
1.22	Exchange rate adjustments to item 1.21	-	-
1.23	Cash at End of Quarter	12,166	12,166

+ See chapter 19 for defined terms.

Payments to Directors of the Entity and Associates of the Directors

Payments to Related Entities of the Entity and Associates of the Related Entities

		Current Quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	170
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions	
	Item 1.24 Reflects amounts paid to directors including director's fees, salaries, superannuation, bonuses and consulting fees (excluding reimbursements).	

Non-Cash Financing and Investing Activities

2.1	Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows	-
2.2	Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest	-

Financing Facilities Available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount Available \$A'000	Amount Used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

For personal use only

Appendix 4C
Quarterly Report for Entities
Admitted on the Basis of Commitments

Reconciliation of Cash


Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current Quarter SA'000	Previous Quarter SA'000
4.1 Cash on hand and at bank	866	481
4.2 Deposits at call	11,300	12,300
4.3 Bank overdraft	-	-
4.4 Other - Bank Guarantee / Trust	-	-
Total: Cash at End of Quarter (item 1.23)	12,166	12,781

Acquisitions and Disposals of Business Entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	-	-
5.2 Place of incorporation or registration	-	-
5.3 Consideration for acquisition or disposal	-	-
5.4 Total net assets	-	-
5.5 Nature of business	-	-

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign Here: 

Print Name: ARWAN DOWLING

Date: 14/4/16

+ See chapter 19 for defined terms.

For personal use only

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.

For personal use only